iBio (NYSE:IBIO) Earns Sell Rating from Analysts at StockNews.com

Equities research analysts at StockNews.com began coverage on shares of iBio (NYSE:IBIO) in a report issued on Wednesday. The brokerage set a “sell” rating on the stock.

iBio Stock Up 192.2 %

NYSE IBIO traded up $2.21 during mid-day trading on Wednesday, hitting $3.36. The stock had a trading volume of 167,444,141 shares, compared to its average volume of 2,891,567. iBio has a 52-week low of $1.02 and a 52-week high of $49.80.

iBio Company Profile

iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.